{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:57:09Z","timestamp":1770843429570,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19654-8","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:57:59Z","timestamp":1760363879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosus"],"prefix":"10.1038","volume":"15","author":[{"given":"Alessandra","family":"Bortoluzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Silvagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Blagojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Bobbio","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Bozzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Canti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Coladonato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Conigliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Crisafulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micol","family":"Frassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Garaffoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Naclerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Orefice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Pettiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Prevete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Alvise","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Scirocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Romana","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Alberto","family":"Scir\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Domenico","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"19654_CR1","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6","volume":"42","author":"SG Barr","year":"1999","unstructured":"Barr, S. G., Zonana-Nacach, A., Magder, L. S. & Petri, M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 42, 2682\u20132688 (1999).","journal-title":"Arthritis Rheum."},{"key":"19654_CR2","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2010.135186","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias, G. K., Salmon, J. E. & Boumpas, D. T. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann. Rheum. Dis. 69, 1603\u20131611 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","volume":"60","author":"IEM Bultink","year":"2021","unstructured":"Bultink, I. E. M., de Vries, F., van Vollenhoven, R. F. & Lalmohamed, A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology 60, 207\u2013216 (2021).","journal-title":"Rheumatology"},{"key":"19654_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez, A. R., Voskuyl, A. E. & Van Vollenhoven, R. F. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat. Rev. Rheumatol. 18, 146\u2013157 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"19654_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/ard-2023-224919","volume":"83","author":"S Pitsigavdaki","year":"2024","unstructured":"Pitsigavdaki, S. et al. Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann. Rheum. Dis. 83, 464\u2013474 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis, A., Tziolos, N., Bertsias, G. & Boumpas, D. T. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 80, 14\u201325 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR9","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand, E. F., Fernandez-Ruiz, R., Blazer, A. & Niewold, T. B. Advances in the management of systemic lupus erythematosus. BMJ 383, e073980 (2023).","journal-title":"BMJ"},{"key":"19654_CR10","unstructured":"Bernardo A Pons-Estel et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <em>Grupo Latino Americano de Estudio del Lupus<\/em>)\u2013Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549 (2018)."},{"key":"19654_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis, A. et al. 2019 update of the joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713\u2013723 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/09612033211012470","volume":"30","author":"GD Sebastiani","year":"2021","unstructured":"Sebastiani, G. D. et al. Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian registry of the Italian Society for Rheumatology. Lupus 30, 1233\u20131243 (2021).","journal-title":"Lupus"},{"key":"19654_CR13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677\u20132686 (2012).","journal-title":"Arthritis Rheum."},{"issue":"7","key":"19654_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg, D. A. et al. BILAG 2004 Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44(7), 902\u2013906 (2005).","journal-title":"Rheumatology"},{"key":"19654_CR15","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"19654_CR16","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","volume":"4","author":"M Piga","year":"2022","unstructured":"Piga, M. et al. Physician global assessment international standardisation consensus in systemic lupus erythematosus: The PISCOS study. Lancet Rheumatol. 4, e441\u2013e449 (2022).","journal-title":"Lancet Rheumatol."},{"key":"19654_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman, D. et al. The development and initial validation of the systemic lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363\u2013369 (1996).","journal-title":"Arthritis Rheum."},{"key":"19654_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo, R. A., Cherkin, D. C. & Ciol, M. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45, 613\u2013619 (1992).","journal-title":"J. Clin. Epidemiol."},{"key":"19654_CR19","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"19654_CR20","doi-asserted-by":"publisher","first-page":"1362699","DOI":"10.3389\/fpubh.2024.1362699","volume":"12","author":"B \u017dlahti\u010d","year":"2024","unstructured":"\u017dlahti\u010d, B., Kokol, P., Bla\u017eun Vo\u0161ner, H. & Zavr\u0161nik, J. The role of correspondence analysis in medical research. Front. Public Health 12, 1362699 (2024).","journal-title":"Front. Public Health"},{"key":"19654_CR21","doi-asserted-by":"publisher","unstructured":"Haynes, W. Benjamini\u2013Hochberg Method. in Encyclopedia of Systems Biology (eds. Dubitzky, W., Wolkenhauer, O., Cho, K.-H. & Yokota, H.) 78\u201378 (Springer, New York, NY, 2013). https:\/\/doi.org\/10.1007\/978-1-4419-9863-7_1215.","DOI":"10.1007\/978-1-4419-9863-7_1215"},{"key":"19654_CR22","doi-asserted-by":"publisher","unstructured":"Sarkar, S. K. Simes\u2019 Test in Multiple testing. in International Encyclopedia of Statistical Science (ed. Lovric, M.) 1325\u20131327 (Springer, Berlin, Heidelberg, 2011). https:\/\/doi.org\/10.1007\/978-3-642-04898-2_516.","DOI":"10.1007\/978-3-642-04898-2_516"},{"key":"19654_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin, B. H. et al. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 105, S1\u2013S69 (2024).","journal-title":"Kidney Int."},{"key":"19654_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225319","author":"M Kostopoulou","year":"2024","unstructured":"Kostopoulou, M., Mukhtyar, C. B., Bertsias, G., Boumpas, D. T. & Fanouriakis, A. Management of systemic lupus erythematosus: A systematic literature review informing the 2023 update of the EULAR recommendations. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/ard-2023-225319 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0961203313519159","volume":"23","author":"R Sakthiswary","year":"2014","unstructured":"Sakthiswary, R. & Suresh, E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23, 225\u2013235 (2014).","journal-title":"Lupus"},{"key":"19654_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF Van Vollenhoven","year":"2012","unstructured":"Van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343\u20131349 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"19654_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/jpm13040691","volume":"13","author":"M Zen","year":"2023","unstructured":"Zen, M. et al. Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the belimumab in real life setting study-joint and skin (BeRLiSS-JS). J. Pers. Med. 13, 691 (2023).","journal-title":"J. Pers. Med."},{"key":"19654_CR28","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/art.41253","volume":"72","author":"M Gatto","year":"2020","unstructured":"Gatto, M. et al. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis Rheumatol. Hoboken NJ 72, 1314\u20131324 (2020).","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"19654_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","volume":"86","author":"L Iaccarino","year":"2018","unstructured":"Iaccarino, L. et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J. Autoimmun. 86, 1\u20138 (2018).","journal-title":"J. Autoimmun."},{"key":"19654_CR30","doi-asserted-by":"publisher","first-page":"e003588","DOI":"10.1136\/rmdopen-2023-003588","volume":"10","author":"J Leaviss","year":"2024","unstructured":"Leaviss, J. et al. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: A prognostic systematic review. RMD Open 10, e003588 (2024).","journal-title":"RMD Open"},{"issue":"2","key":"19654_CR31","first-page":"CD010668","volume":"2","author":"JA Singh","year":"2021","unstructured":"Singh, J. A., Shah, N. P. & Mudano, A. S. Belimumab for systemic lupus erythematosus. Cochrane Database Syst. Rev. 2(2), CD010668 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"19654_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead707","author":"S Lin","year":"2023","unstructured":"Lin, S. et al. Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/kead707 (2023).","journal-title":"Rheumatology"},{"key":"19654_CR33","doi-asserted-by":"publisher","first-page":"e000253","DOI":"10.1136\/lupus-2017-000253","volume":"5","author":"J Tian","year":"2018","unstructured":"Tian, J. et al. Risk of adverse events from different drugs for SLE: A systematic review and network meta-analysis. Lupus Sci. Med. 5, e000253 (2018).","journal-title":"Lupus Sci. Med."},{"key":"19654_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/0961203312469259","volume":"22","author":"D Wallace","year":"2013","unstructured":"Wallace, D. et al. Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 22, 144\u2013154 (2013).","journal-title":"Lupus"},{"key":"19654_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2307\/2090964","volume":"30","author":"NB Ryder","year":"1965","unstructured":"Ryder, N. B. The cohort as a concept in the study of social change. Am. Sociol. Rev. 30, 843\u2013861 (1965).","journal-title":"Am. Sociol. Rev."},{"key":"19654_CR36","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.42620","volume":"75","author":"E Materne","year":"2023","unstructured":"Materne, E. et al. Comparative risks of infection with belimumab versus oral immunosuppressants in patients with nonrenal systemic lupus erythematosus. Arthritis Rheumatol. 75, 1994\u20132002 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"19654_CR37","doi-asserted-by":"publisher","first-page":"996662","DOI":"10.3389\/fimmu.2022.996662","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu, Z., Cheng, R. & Liu, Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front. Immunol. 13, 996662 (2022).","journal-title":"Front. Immunol."},{"key":"19654_CR38","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","volume":"4","author":"EF Morand","year":"2022","unstructured":"Morand, E. F. et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: A post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 4, e282\u2013e292 (2022).","journal-title":"Lancet Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19654-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:58:01Z","timestamp":1760363881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19654-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19654"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19654-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B. reports consulting\/speaker\u2019s fees from AstraZeneca and GSK.  P.C. reports consulting fees from Astra Zeneca and GSK. F.F. reports consulting\/speaker\u2019s fees from AstraZeneca and GSK.  M.G. reports consulting\/speaker\u2019s fees from AstraZeneca and GSK. S.M. reports consulting\/speaker\u2019s fees from AstraZeneca E.S. reports consulting\/speaker\u2019s fees from AbbVie, Alfa-Sigma, Lilly, UCB, Novartis A.D. reports consulting\/speaker\u2019s fees from GSK, AstraZeneca, BMS, Johnson & Johnson, Biogen, Ventus, Otsuka, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35721"}}